With rapidly aging populations and declining birth rates, many countries are facing acute healthcare challenges, including China. As China continues to develop and improve its healthcare ecosystem, the healthcare market is expected to grow to RMB16 trillion (~SGD3.29 trillion) in 2030 (McKinsey, 2018). Notably, China’s thriving medtech industry offers a myriad of opportunities. To accelerate growth of this strategic emerging industry, China has been making rapid regulatory reforms since 2015. Such moves have spurred faster development of, and approvals for medical products. From 2015 to 2019, Chinese foreign trade in medical devices grew by nearly 10% each year, outpacing worldwide growth (Deloitte, 2021). Today, China accounts for around 20% of the global medical device market, and its market share is expected to grow further (Deloitte, 2021). Singapore Biodesign, a global affiliate of the Stanford Byers Center for Biodesign, has partnered with Enterprise Singapore (Enterprise SG) to deliver an exciting Open Access Lecture (OAL) on the latest trends and opportunities in China’s Medtech Industry. To help Singapore medtech enterprises understand the latest trends and opportunities in China, we have invited industry experts with the relevant market knowledge to share their insights: • Ms. Charis Goh, Principal, Head of Private Equity, Heritas Capital • Dr. Lee Phin Peng, Deputy Programme Director, Singapore Biodesign • Dr. Ng Xu Wen, Senior Associate, Innoventures • Mr. Peh Ruey Feng, Head of International R&D and Innovation, Genesis Medtech Highlights • Understand recent developments and opportunities in China’s medtech sector • Learn about channels that Singapore medtech enterprises can leverage to enter the China market • Gain insights on how industry experts and companies have successfully established themselves in China